AI Article Synopsis
Article Abstract
Aims: The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This manuscript presents 12-month interim data.
Materials And Methods: TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide. Data on clinical characteristics, GLP-1 RA persistence and treatment patterns of glucose-lowering medication were collected at initiation of first injectable therapy and by 12 months.
Results: By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy. Both cohorts presented a high probability [95% confidence interval (CI)] of GLP-1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)] and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, -1.18 (-1.27 to -1.08); liraglutide, -1.15 (-1.26 to -1.05)] with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline. Mean weight (95% CI) change from baseline was -3.2 kg (-3.6 to -2.8) for dulaglutide and -3.4 kg (-3.9 to -3.0) for liraglutide. Slight changes in concomitant medications were observed compared with baseline.
Conclusions: In the real-world setting, dulaglutide and liraglutide cohorts achieved good persistence with similarly improved glycaemic control that was accompanied by weight loss at 12 months, consistent with previous clinical trial results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804517 | PMC |
| http://dx.doi.org/10.1111/dom.14823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The cardiovascular outcomes between liraglutide and dulaglutide among different chronic kidney disease (CKD) stages in patients with type 2 diabetes.
Endocr Pract
December 2024
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:
Objective: This study aimed to evaluate the effectiveness and safety of two glucagon-like peptide-1 receptor agonists (GLP-1 RAs), liraglutide and dulaglutide, in patients with T2DM at various stages of CKD. In addition to analyzing MACE as the primary outcome, kidney function deterioration, renal disease, and other drug-related safety events, such as urinary tract infections, pancreatitis, amputations, and cancers were measured.
Research Design And Methods: This retrospective analysis included 362,842 T2DM patients from the Chang Gung Research Database (CGRD) between 2011 and 2019, identifying 2,830 GLP-1 RA users.
Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.
Curr Med Res Opin
December 2024
Department of Cardiology, Lincoln Medical Center, Bronx, NY, USA.
Article Synopsis
- GLP-1 receptor agonists (GLP-1RAs) show a modest decrease in low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) based on a review of clinical trials.
- The analysis found no significant impact on triglycerides, very low-density lipoprotein cholesterol (VLDL-C), or high-density lipoprotein cholesterol (HDL-C).
- Weight changes did not have a notable effect on LDL-C or TC levels among study participants.
GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Otol Neurotol
January 2025
Cedars-Sinai Medical Center, Division of Otolaryngology-Head and Neck Surgery, Los Angeles, CA.
Introduction: GLP-1 receptor agonists (GLP-1 RAs) have gained traction in the management of obesity. There is limited literature on the implications of GLP-1 RAs in the field of otolaryngology.
Methods: We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
Diabetol Metab Syndr
December 2024
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Alsharqia, Egypt.
Background And Aim: The association between biliary disorders with weight reduction enhanced by GLP-1RAs was observed frequently, nevertheless, the relative risk of the clinically relevant cholelithiasis was not specified clearly among different GLP-1RAs.
Methods: 308 patients with type 2 diabetes mellitus (T2D) were recruited and divided into 4 groups; liraglutide, dulaglutide, semaglutide, versus control group; comprised of 69, 76, 71, and 92, respectively. Clinical history, examination, laboratory, and radiology tests were implemented.
Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.
BMJ Open
December 2024
Shanghai Health Development Research Center, Shanghai Medical Information Center, Shanghai, China
Objectives: To analyse the impacts of multiple rounds of National Centralised Drug Procurement Policy (NCDP) and National Drug Price Negotiation Policy (NDPN) on the utilisation, expenditure and daily cost of novel hypoglycaemic drugs.
Design: The drug procurement data were obtained from the Shanghai Medical Procurement Agency between January 2016 and December 2022. We examined changes in volume, expenditure of overall hypoglycaemic drugs by descriptive analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!